Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-08-07

FDA Approved: GABAPENTIN — Supplemental Application (Ajenat Pharmaceuticals LLC)

View source ↗

Summary

FDA approves a supplemental application for Gabapentin submitted by Ajenat Pharmaceuticals LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gabapentin (Gabapentin)

Snippet

SUPPL AP for GABAPENTIN (GABAPENTIN)